KUSTE is a Phase2 clinical stage Biopharma with option on WW rights on anti-inflammatory drug proven safe and effective in hundreds of patients for a variety of therapies (ear and eye diseases, in local delivery). First target is Interstitial Cystitis which today has no cure for 1.7m + patients (USA EU JAPAN, only); 80%+ patients are women. Today Hyaluronic Acid is used as a symptom relief not as a cure, contrary to common bacterial cystitis.